Background
==========

Axillary lymph node status is the most important prognostic factor for predicting survival in cases of invasive breast cancer \[[@b1-medscimonit-23-4102]--[@b5-medscimonit-23-4102]\], and axillary lymph node dissection (AxLND) has been widely accepted as the standard treatment in patients with invasive breast cancer because of its accurate assessment of lymph nodes status. However, sentinel lymph node biopsy (SLNB), as a minimally invasive surgical procedure, has emerged as the preferred technique for axilla staging especially in patients who are free of clinically detected lymph node metastasis \[[@b6-medscimonit-23-4102]--[@b9-medscimonit-23-4102]\]. Moreover, compared with the standard AxLND, there are two advantages to SLNB. First, it has better cosmetic results \[[@b10-medscimonit-23-4102]\] and is associated with less arm and shoulder complications, including upper limb pain, sensory loss, lymphedema, and lymphangiosarcoma \[[@b11-medscimonit-23-4102]--[@b13-medscimonit-23-4102]\]. Second, it can provide a rapid intraoperative diagnosis and help surgeons to decide whether AxLND should be performed.

However, the reported incidence of SLN metastasis varies from 33.2--39% \[[@b14-medscimonit-23-4102]--[@b16-medscimonit-23-4102]\] and approximately 60--70% of patients suffered from unnecessary invasive axilla surgery. This raises the question of whether we can identify appropriate candidates for whom SLNB might be avoided. Prior work in this area has mostly focused on predictive factors for AxLN metastasis, whereas the role of predictors for clinically negative breast cancer patients is uncertain. To date, predictive factors for SLN metastasis have not yet been clarified. Therefore, we reviewed consecutive patients with early breast cancer who underwent breast and SLN surgical procedure in our hospital to determine the predictors for SLN metastasis.

Material and Methods
====================

Patients
--------

Inclusion criteria was as follows: 1) histologically proven invasive breast carcinoma; 2) no evidence of AxLN involvement or distant metastasis; 3) core needle biopsy (CNB) performed and pathological parameters, including tumor histological grade, ER, PR, HER2, Ki67 determined before surgery. SLNB with tracer methylene blue was implemented before breast surgical procedure, and AxLND (level I and II axillary lymph node) was then carried out if SLN was confirmed positive by frozen section examination intraoperatively. Every patient signed informed consent.

Exclusion criteria included: 1) male gender; 2) tumor size larger than 5 cm; 3) previous breast cancer history; 4) previous neoadjuvant therapy for breast carcinoma; 5) previous ipsilateral axilla surgery history; 6) bilateral breast cancer; 7) inflammatory breast cancer; and 8) pregnant with breast cancer.

Data collection
---------------

Medical records of eligible patients were reviewed and clinicopathological data were collected, including: patient age, gender, menstrual status, breast cancer family history, BMI; and tumor features such as tumor size, laterality of the tumor, histological grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), and Ki67 index. The criteria of HER2 positivity was defined as either IHC3+ or gene amplification by fluorescence *in situ* hybridization (FISH).

Statistical analysis
--------------------

Univariate analysis with chi-squared test or Fisher's exact test was performed to detect predictors for SLN metastasis. Then, multivariate analysis, including all variables from the univariate analysis that were related to SLN status, was performed to test factors' independence. Statistical significance was defined as *p*\<0.05; hazard ratio (HR) and 95% confidence intervals (CI) were also calculated. Statistical tests were two-sided, and analyses were performed using SPSS v.19.0 Software (SPSS, Chicago, IL, *<http://www.spss.com>*).

Results
=======

Patient characteristics and SLNB
--------------------------------

A total of 561 breast cancer patients who had breast surgery and SLNB at Ningbo Medical Center Lihuili Eastern Hospital between March 2009 and September 2016 were considered for the study. Of these, 144 cases were excluded from the study for the following reasons: *in situ* carcinoma (123 cases), bilateral breast cancer (six cases), male breast cancer (two cases), SLNB failure (eight cases), and only one SLN detected (five cases). Thereafter, 417 eligible cases were enrolled in the study. All patients were female with median age of 51 years old (range 23--80 years). Patient characteristics, tumor characteristics and surgical procedure are presented in [Table 1](#t1-medscimonit-23-4102){ref-type="table"} and included: patient age, menstrual status, BMI, breast cancer family history, tumor size, laterality of the tumor, histological grade, ER, PR, HER2, Ki67, and molecular subtype, and surgical procedure.

In all, 2,005 SLNs were detected, with the average of 4.81±2.15 (median: 5, range: 2--9). The majority of patients (95.2%) had more than two SLNs, and 4.8% of patients had only two SLNs. [Figure 1](#f1-medscimonit-23-4102){ref-type="fig"} demonstrates the distribution of SLN numbers. Six patients had a negative primary diagnosis based on frozen section examination but were confirmed positive on final pathological examination, and another 90 patients were positive on both pathological examinations. Of these 96 (23%) were SLN-positive patients, 92 (22.0%) of patients had macro-metastasis, and four (1.0%) of patients had micro-metastasis. [Figure 2](#f2-medscimonit-23-4102){ref-type="fig"} (pie picture) shows the percentages of SLN metastasis with different SLN metastasis numbers: 96 patients (23.0%) were SLN positive on final pathology results,

Association between clinicopathological factors and SLN status
--------------------------------------------------------------

Our study found that patient age, tumor size, histological grade, and Ki67 index were associated with the presence of SLN metastasis, while other factors had no relationship with SLN metastasis ([Table 2](#t2-medscimonit-23-4102){ref-type="table"}). Four predictive factors which were confirmed to be associated with SLN metastasis by univariate analysis were brought into the multivariate logistic regression analysis model, which found that patient age, tumor size, and histological grade were independent predictive factors ([Table 3](#t3-medscimonit-23-4102){ref-type="table"}).

The SLN metastasis ratio on different subgroups
-----------------------------------------------

The three risk factors for SLN metastasis were age younger than forty years old, tumor size larger than 2 cm, and histological grade III. The combination of three risk factors had eight different scenarios, and presented three different levels of SLN metastasis: 1) high-risk group, this group included patients with all three risk factors and SLN metastasis with a ratio of 66.7% (8/12); 2) moderate-risk group, this group included patients with one or two risk factors with a ratio of 31.4% (55/175); and 3) low-risk group, this group included patients with no aforementioned risk factors, with a ratio of 14.3% (33/230).

Discussion
==========

Dual tracer technique with isotopic tracer and blue dye tracer has a higher detection rate compared to either of these tracers alone \[[@b17-medscimonit-23-4102],[@b18-medscimonit-23-4102]\]. It is a great pity that isotopic tracer cannot be used routinely in China except in few large-scale medical centers, so blue dye tracer is the first and the sole choice for SLNB for early breast cancer patients. Three blue dye tracers used in clinical research and practice are isosulfan blue, patent blue dye, and methylene blue dye, but none of these are considered the gold standard for SLNB according to the current literatures \[[@b17-medscimonit-23-4102],[@b19-medscimonit-23-4102]--[@b21-medscimonit-23-4102]\]. In the present study, we used a single tracer technique with methylene blue dye and identified an average of 4.81 SLNs per patient, and three or more SLNs were detected in 95.2% of patients, which together demonstrated that SLNB with methylene blue tracer technique was a reasonable and feasible surgical procedure, supported further by the fact that when three and more SLNs were identified, the false negative rate decreased to the acceptable 5% level recommended by the American Society of Clinical Oncology (ASCO) guideline \[[@b22-medscimonit-23-4102]\].

In our series of 417 early breast cancer patients, the presence of SLN metastasis was 23.0%, which was lower than in previous reports, with an incidence range reported in the literature of 33.2--39%) \[[@b14-medscimonit-23-4102]--[@b16-medscimonit-23-4102]\]. This difference may be due to the higher percentage of T1 tumor in our study (73.9%) compared to about 50% in other studies, which might account for the lower metastasis incidence in our study.

One significant finding was the three factors that were determined as independent predictor for SLN metastasis, both in univariate and multivariate analysis, namely patient age, tumor size, and histological grade. Another important finding was that the combination of patient age, tumor size, and histological grade can effectively discriminate patients with differential risk of SLN metastasis.

Young breast cancer or breast cancer in young women refers to patients with breast cancer who are younger than 35--40 years old, and presented with more aggressive biological behavior and unfavorable prognosis when compared to their counterparts. In the present study, we used 40 years of age as the cutoff point, and found that patient age at the time of diagnosis was significantly associated with a high risk of SLN metastasis. This predictive effect of age on nodal involvement was consistent with earlier evidence that indicated that breast tumors can be more aggressive in younger women \[[@b23-medscimonit-23-4102]--[@b25-medscimonit-23-4102]\]. Inconsistent results have been reported in recent literature \[[@b26-medscimonit-23-4102],[@b27-medscimonit-23-4102]\], and there are obvious differences in the cutoff point chosen for age, which was younger in our study (40 years old) than has been reported in some other studies (50 years old).

Tumor size was the second predictor for SLN metastasis in our study, which was found to be predictive of axillary lymph node metastasis. Other studies have found that even in patients with tumor size less than 5--10 mm, there was a significant nodal metastasis in 5--15% of cases \[[@b28-medscimonit-23-4102]--[@b31-medscimonit-23-4102]\]. A retrospective analysis of 893 cases showed that the rate of node metastasis increased from 11% to 36% as tumor size increased from 10 mm to 25 mm \[[@b32-medscimonit-23-4102]\]. Similar results were also found in our study: 18.8% of patients with tumors no larger than 20 mm and 34.9% of patients with tumor larger than 20 mm had SLN involved.

Previous studies have shown that histological grade has important prognostic value, which is equivalent to that of lymph node status \[[@b22-medscimonit-23-4102]\] and greater than that of tumor size \[[@b33-medscimonit-23-4102],[@b34-medscimonit-23-4102]\]. A retrospective study demonstrated that patients with grade I, stage II disease had the same survival as those with grade III, stage I disease \[[@b35-medscimonit-23-4102]\]. However, the value of histological grade on axillary lymph node metastasis has been controversial. Histological grade was the third predictor for SLN metastasis in the present study, which was in concordance with previous reports \[[@b36-medscimonit-23-4102],[@b37-medscimonit-23-4102]\]. However, in a recent report, tumor histological grade was related with SLN metastasis by univariate analysis either in overall sample or in luminal subgroup, but lost predictive value by multivariate logistic regression analysis \[[@b26-medscimonit-23-4102]\].

The most important result in our study was that when three predictors were considered together, all patients could be stratified into three SLN metastasis levels: 1) high-risk group, which included the patients with all of three risk factors; 2) moderate-risk group, which included the patients with one to two risk factors; and 3) low-risk group, which included patients with none of the aforementioned risk factors. Our results suggested that the combinations of patient age, tumor size, and histological grade could effectively discriminate between patients with differential SLN metastasis. In the present study, more than half of the patients were in the low-risk group, in which the incidence was 14.3%; and thus the remaining 85.7% of patients might avoid axilla surgery theoretically due to negative lymph node status. Our results also provided evidence for rational decision-making in specific clinical situations, especially for patients with low risk of lymph node metastasis. For instance, in elderly patients who cannot tolerate or who do not have any contraindications for general anesthesia, simple treatment under local anesthesia with wide excision of the primary tumor without axilla surgery may be a reasonable choice. In addition, an immediate autologous breast reconstruction should be primarily considered in low-risk patients, while a delayed reconstruction may be preferred in high-risk patients.

The limitations of the study should be acknowledged. First, this was a retrospective, single-institution study with small sample size, which may decrease the reliability of the present study findings. Second, in our study a single tracer technique with methylene blue dye was applied, which was not the preferred technique recommended by the National Comprehensive Cancer Network (NCCN). Third, lymphovascular invasion (LVI) has been described as an independent predictor of node involvement in prior reports \[[@b38-medscimonit-23-4102]--[@b40-medscimonit-23-4102]\], but it could not be evaluated in our study which used diagnostic core-needle-biopsy of the primary tumor, a technique that has limited ability to assess LVI, and thus we could not verified LVI in our study.

Conclusions
===========

In conclusion, though it was a retrospective, single-institution study, the results presented may be useful for managing select groups of patients who, due to comorbidities or refusal, have avoided surgical interventions in the axilla. Currently, a randomized, double-blind, multicenter clinical trial is recruiting more than 1,000 patients to verify whether, in the presence of a negative preoperative axillary assessment, SLNB can be spared and the decision on adjuvant medical treatment be made according to the biology of the tumor.
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###### 

Clinicopathologic characteristics of early breast cancer patients.

                           Numbers (n)   Percentage (%)
  ------------------------ ------------- ----------------
  Age (years)                            
   \<40                    68            16.3
   40--60                  282           67.6
   \>60                    67            16.1
  Menstrual status                       
   Premenopausal           253           60.7
   Postmenopausal          164           39.3
  BMI                                    
   ≤25                     273           65.5
   \>25                    144           34.5
  Family history                         
   Yes                     27            6.5
   No                      390           93.5
  Laterality of tumor                    
   Left                    210           50.4
   Right                   207           49.6
  Tumor size (cm)                        
   \<1 cm                  78            18.7
   1--2 cm                 230           55.2
   \>2 cm                  109           26.1
  Histological grade                     
   I                       62            14.9
   II                      270           64.7
   III                     85            20.4
  Histological type                      
   IDC                     388           93.0
   ILC                     4             1.0
   Mucinous                20            4.8
   Medullary               5             1.2
  ER                                     
   Negative                109           26.1
   Positive                308           73.9
  PR                                     
   Negative                127           30.5
   Positive                290           69.5
  HER2                                   
   Negative                341           81.8
   Positive                76            18.2
  Ki67                                   
   Low expression index    281           67.4
   High expression index   136           32.6
  Molucular subtype                      
   Luminal A-like          118           28.3
   Luminal B-like          200           48.0
   HER2 overexpression     61            14.6
   Triple negative         38            9.1
  Surgery                                
   BCS + SLNB              254           60.9
   BCS + ALND              70            16.8
   Mastectomy + SLNB       48            11.5
   MRM                     45            10.8

IDC -- invasive ductal carcinoma; ILC -- invasive lobular carcinoma; ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor 2; BCS -- breast conserving surgery; SLNB -- sentinel lymph node biopsy; ALND -- axillary lymph node dissection; MRM -- modified radical mastectomy.

###### 

Relationship of clinicopathologic factors for SLN metastasis.

  Variable                  SLNM (n)   SLN-NM (n)   p Value   Hazard ratio   95%CI
  ------------------------- ---------- ------------ --------- -------------- --------------
  Age                                                                        
   \<40 years               24         44                                    
   ≥40 years                72         277          0.009     2.098          1.198--3.677
  Menstrual status                                                           
   Premenopausal            32         132                                   
   Postmenopausal           64         189          0.171     0.716          0.443--1.156
  BMI                                                                        
   ≤25                      58         215                                   
   \>25                     38         106          0.235     0.753          0.470--1.205
  Family history                                                             
   Yes                      9          18                                    
   No                       87         203          0.188     1.741          0.756--4.013
  Laterality of the tumor                                                    
   Left                     52         158                                   
   Right                    44         163          0.392     1.219          0.772--1.926
  Tumor size                                                                 
   ≤2 cm                    58         250                                   
   \>2 cm                   38         71           0.001     0.433          0.266--0.705
  Histological grade                                                         
   I--II                    62         270                                   
   III                      34         51           0.000     0.344          0.206--0.576
  ER                                                                         
   Positive                 76         232                                   
   Negative                 20         89           0.178     1.458          0.841--2.526
  PR                                                                         
   Positive                 68         222                                   
   Negative                 28         99           0.754     1.083          0.657--1.785
  HER2                                                                       
   Positive                 16         60                                    
   Negative                 80         261          0.652     0.870          0.475--1.594
  Ki67                                                                       
   Low index                54         224                                   
   High index               42         97           0.014     0.557          0.349--0.889
  Molucular subtype                                                          
   Triple negative          6          32                                    
   Non-triple negative      90         289          0.267     0.602          0.244--1.486

SLNM -- sentinel lymphnode metastasis; SLN-NM -- sentinel lymph node not metastasis; CI -- confidence interval; ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor-2.

###### 

Multivariate analysis for SLN metastasis predictive parameters

  Variable             SLNM (n)   SLN-NM (n)   p Value   Hazard ratio   95%CI
  -------------------- ---------- ------------ --------- -------------- --------------
  Age                                                                   
   \<40 years          24         44                                    
   ≥40 years           72         277          0.011     2.188          1.198--4.001
  Tumor size                                                            
   ≤2 cm               58         250                                   
   \>2 cm              38         71           0.028     0.616          0.401--0.949
  Histological grade                                                    
   I--II               62         270                                   
   III                 34         51           0.003     0.408          0.224--0.743
  Ki67                                                                  
   Low index           54         224                                   
   High index          42         97           0.574     0.851          0.485--1.494

SLNM -- sentinel lymph node metastasis; SLN-NM -- sentinel lymph node not metastasis; CI -- confidence interval
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